Transcenta Announces Completion of First Patient Assay in Radionuclide Labeled CLDN18.2 Antibody PET-CT Imaging Study
SUJOU, China, June 1, 2021 / PRNewswire / – Transcenta Holding Limited (âTranscentaâ), a global biotherapeutics company with fully integrated capabilities in the discovery, development and manufacture of antibody therapeutics, announced the completion of the first patient assay in the PET-CT imaging study of the radionuclide-labeled CLDN18.2 antibody.
The study was led by the professor Lin Shen and Dr Hua Zhu, from Beijing Cancer Hospital, the aim of the study is to build a non-invasive approach to 124I-18B10 PET-CT to detect CLDN18.2 expression of tumor lesions in patients with gastrointestinal tumors and other solid tumors, and to identify patients who have received treatment targeting CLDN18.2. Current preclinical results have shown that the antibody probe has high specificity for CLDN18.2 and is specifically enriched in the CLDN18.2 positive tumor site in tumor-bearing mice rather than in normal tissue. The results of this study were presented as a poster at the ESMO Targeted Anticancer Therapies 2021 Virtual Congress in March and the summary was also published in Annals of Oncology, 2021 (32). An investigator-initiated clinical trial (NCT04883970) is approved for enrollment. The first subject received an intravenous injection of 124I-18B10 antibody probe last week and finished PET-CT imaging study.
âWe are working with the Beijing Cancer Hospital to explore the potential of 124Antibody I-18B10 as a non-invasive diagnostic reagent, “said Dr. Michael shi, EVP, Head of Global R&D and CMO of Transcenta, âIn the future, we hope that radionuclide tracer technology can be used in the non-invasive, precise and targeted medical diagnosis and treatment of gastrointestinal cancer.
“As a novel imaging agent, the radionuclide-labeled antibody 18B10 has great potential to be further developed as a non-invasive diagnostic technology for CLDN18.2 positive cancer patients, and may provide a novel auxiliary tool for the diagnosis of CLDN18.2- expressed tumors and the identification of future metastatic sites. ” said the teacher Lin Shen from Beijing Cancer Hospital.
About Transcenta Holding Limited.
Transcenta is a global clinical-stage biotherapeutics company that fully integrates the discovery, development and manufacture of antibody-based biotherapeutics. Transcenta has established a global footprint, with a head office and translational research and discovery center in Suzhou, a process and product development center, and a manufacturing facility in Hangzhou, and the clinical development centers of Beijing, Shanghai and Canton in China and in Princeton, United States and External Partnership Center at Boston, US. Transcenta is developing a panel of nine antibody molecules for oncology and certain non-oncological indications, in particular bone and kidney disorders. During the last financing, the company raised more than $ 342 million leading global investors. For more information, please visit www.transcenta.com.
Public relations: [emailÂ protected]
Business development: [emailÂ protected]
SOURCE Transcenta Holding Limited